Research Topics
| Shibo JiangSummaryAffiliation: New York Blood Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1Jing He Huang
Laboratory of Immunology, Department of Biology, Tsinghua University, Protein Science Laboratory of the Ministry of Education, Beijing 100084, P R China
J Biol Chem 282:6143-52. 2007..Further characterization of the gp41 core-binding motifs may shed light on the alternative mechanism by which HIV-1 enters into the target cell...- An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virusGuangyu Zhao
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
Virol J 7:151. 2010..In this report, we investigated whether such M2e-MAP presenting the H5N1-M2e consensus sequence can afford heterosubtypic protection from lethal challenge with the pandemic 2009 H1N1 virus... - Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patientsZhiliang Cao
State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Virol J 7:299. 2010..However, the antigenicity and immunogenicity of RBD in humans need to be characterized... - An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza virusesGuangyu Zhao
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
Virol J 7:9. 2010.... - Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of ChinaLiying Ma
State Key Laboratory for Infectious Disease Control and Prevention, National Center for AIDS STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, PR China
Retrovirology 6:45. 2009..The aim of this study is to characterize the genotypic and phenotypic properties of HIV-1 CRF07_BC isolates in comparison with those of the subtype B' (Thailand B) which is prevalent in the former plasma donors (FPDs) in China... - Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmissionLin Li
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
Retrovirology 7:37. 2010..Here we sought to replace bovine protein with an animal protein of non-bovine origin and substitute HP with another anhydride for the development of anti-HIV microbicide for preventing HIV sexual transmission... - N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusionShibo Jiang
Lindsley F Kimball Research Institute, New York Blood Center, 310 E 67th St, New York, NY 10021, USA
Antimicrob Agents Chemother 48:4349-59. 2004..Therefore, NB-2 and NB-64 can be used as lead compounds toward designing and developing more potent small molecule HIV-1 fusion inhibitors targeting gp41... - Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccinesShibo Jiang
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Protein Cell 1:342-54. 2010..Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines... - Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41Shibo Jiang
Lindsley F Kimball Research Institute, New York Blood Center, NY 10065, USA
Bioorg Med Chem Lett 21:6895-8. 2011.... - Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41Shibo Jiang
Lindsley F Kimball Research Institute, New York Blood Center, New York 10065, United States
J Med Chem 54:572-9. 2011..By contrast, molecular docking of 12i, a less active compound containing a pyrrole instead of a furan ring, indicated a completely different orientation from 12b and 12m and missed critical interactions... - Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocketXiaowen Yu
School of Life Sciences, Tsinghua University, Key Laboratory for Protein Sciences of MOE, Beijing 100084, China
J Virol 86:589-93. 2012..This report provides insights into the mechanisms of drug resistance, with implications for the design of novel HIV fusion and entry inhibitors... - SARS vaccine developmentShibo Jiang
New York Blood Center, New York, New York 10021, USA
Emerg Infect Dis 11:1016-20. 2005..This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines... - 3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1Lin Li
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China
Antimicrob Agents Chemother 54:1700-11. 2010..Because of the widespread availability and established safety profile of OVA, HP-OVA has good potential to be developed as an effective, safe, and affordable microbicide for prevention of HIV sexual transmission... - A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, New York, New York 10065, USA
Viral Immunol 23:211-9. 2010..These results suggest that the recombinant RBD219-CHO protein has great potential for the development of an effective and safe SARS subunit vaccine... - Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodiesYuxian He
Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
J Immunol 174:4908-15. 2005..005 to 6.569 microg/ml. Therefore, the RBD of SARS S protein contains multiple conformational epitopes capable of inducing potent neutralizing Ab responses, and is an important target site for developing vaccines and immunotherapeutics... - ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formationHongtao Wang
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
Antimicrob Agents Chemother 53:4987-98. 2009.... - Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike proteinYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10021, USA
J Immunol 176:6085-92. 2006.... - Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccineYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10021, USA
Vaccine 24:5498-508. 2006..These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV, and this panel of novel mAbs can be used as tools for studying the structure of S protein and for guiding SARS vaccine design... - Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitorsShuwen Liu
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Lancet 363:938-47. 2004..CP-1 might be modifiable to increase its anti-SARS-CoV activity and could be further developed as an antiviral agent for treatment or prophylaxis of SARS-CoV infection... - Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunityLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Virology 393:144-50. 2009..coli and insect cells... - Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine designYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
J Virol 80:5757-67. 2006..This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein... - Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cellsYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
J Immunol 182:4005-16. 2009.... - Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41Shuwen Liu
Lindsley F. Kimball Research Institute, The New York Blood Center, 310 E 67th Street, New York, NY 10021, USA
Biochim Biophys Acta 1723:270-81. 2005..These results indicate that tea, especially black tea, may be used as a source of anti-HIV agents and theaflavin derivatives may be applied as lead compounds for developing HIV-1 entry inhibitors targeting gp41... - Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccinesYuxian He
Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10021, USA
Virology 334:74-82. 2005..These data provide important information for understanding the antigenicity and immunogenicity of SARS-CoV and for designing SARS vaccines... - Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitorsZhi Qi
Lindsley F Kimball Research Institute, New York Blood Center, New York, New York 10065, USA
J Biol Chem 283:30376-84. 2008.... - Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entryYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, New York, New York 10021, USA
J Biol Chem 282:25631-9. 2007..Collectively, these data suggest that conserved Lys574 plays a critical role in 6-HB formation and HIV-1 infectivity, and may serve as an important target for designing anti-HIV drugs... - Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirusYuxian He
Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, 310 East 67th St, New York, NY 10021, USA
J Clin Microbiol 43:3718-26. 2005..These findings provide important information for developing SARS diagnostics and vaccines... - Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirusYuxian He
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
J Clin Microbiol 42:5309-14. 2004..These results suggest that the above antigenic sites on the N protein are important in eliciting humoral immune response against SARS-CoV in humans and animals and can be used as antigens for developing diagnostic tests... - The spike protein of SARS-CoV--a target for vaccine and therapeutic developmentLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10065, USA
Nat Rev Microbiol 7:226-36. 2009..In this Review, we highlight recent advances in the development of vaccines and therapeutics based on the S protein... - Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entryYuxian He
Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Biochem Biophys Res Commun 325:445-52. 2004..However, caution should be taken in using the inactivated SARS-CoV as a vaccine since it may also cause harmful immune and/or inflammatory responses... - Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cellsLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Biochem Biophys Res Commun 384:486-90. 2009..These results suggest that the recombinant RBD produced in an established stable cell line maintains strong immunogenicity with high potential for use as an effective and economic subunit SARS vaccine... - HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptidesShuwen Liu
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
J Biol Chem 282:9612-20. 2007..The multiple functional domains in gp41 CHR and their binding partners may serve as targets for rational design of new anti-HIV-1 drugs and vaccines... - Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infectionLin Li
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
J Acquir Immune Defic Syndr 56:384-92. 2011..We intended to evaluate potential the synergistic anti-HIV-1 effect of HP-OVA in combination with antiretroviral drug (ARV)-based microbicide candidates... - Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4Qian Zhao
Laboratory of Molecular Modeling and Drug Design of the Lindsley F Kimball Research Institute of The New York Blood Center, 310 E 67th Street, New York, NY 10021, USA
Virology 339:213-25. 2005.... - Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Proc Natl Acad Sci U S A 105:16332-7. 2008..These findings suggest that CP32M can be further developed as an antiviral therapeutic against multidrug resistant HIV-1... - A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activityYuxian He
Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10021, USA
Biochem Biophys Res Commun 344:106-13. 2006..Taken together, these data provide direct evidence to show that a single amino acid residue at key position in the RBD can determine the major function of SARS-CoV S protein and imply for designing SARS vaccines and therapeutics... - A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated miceZhi Qi
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Biochem Biophys Res Commun 398:506-12. 2010..These findings provide an important clue for developing recombinant gp41 PFI mimetics-based HIV vaccines... - Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibitionYuxian He
Lindsley F Kimball Research Institute, New York Blood Center, 310 East 67th Street, New York, NY 10021, USA
J Virol 82:11129-39. 2008..Taken together, these data suggest that the salt bridge between the N- and C-terminal heptad repeat regions of the fusion-active HIV-1 gp41 core structure is critical for viral entry and inhibition... - Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitorsChungen Pan
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
AIDS 23:639-41. 2009..These findings suggest that application of enfuvirtide and sifuvirtide in combination may improve their efficacy and resistant profile, leading to a reduction of the dosage and frequency of drug use... - Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodiesLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Biochem Biophys Res Commun 397:580-5. 2010.... - Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120Shuwen Liu
Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10021, USA
J Biol Chem 280:11259-73. 2005..These new findings imply that T-20 inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. Further elucidation of the mechanism of action of T-20 will provide new target(s) for development of novel HIV entry inhibitors... - Four-way ligation for construction of a mammalian cell-based full-length antibody display libraryIvan Zhou
Antiviral Research Center, School of Pharmaceutical Science, Southern Medical University, Guangzhou, China
Acta Biochim Biophys Sin (Shanghai) 43:232-8. 2011..Using this strategy, only 2 weeks were required to successfully construct high-quality, full-length human antibody libraries... - HIV-1 gp41 fusion intermediate: a target for HIV therapeuticsChungen Pan
Laboratory of Viral Immunology, Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
J Formos Med Assoc 109:94-105. 2010..Here, we present an overview of the current development of anti-HIV drugs, particularly those targeting the gp41 fusion intermediate... - Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infectionShuwen Liu
Lindsley F. Kimball Research Institute, New York Blood Center, 310 E 67th St, New York, NY 10021, USA
Antimicrob Agents Chemother 49:1830-6. 2005..This suggests that the combination of CAP and UC781 represents a promising candidate microbicide for prevention of sexual transmission of HIV-1... - Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccineYuxian He
Viral Immunology Laboratory, Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Biochem Biophys Res Commun 324:773-81. 2004..This suggests that RBD can induce highly potent neutralizing antibody responses and has potential to be developed as an effective and safe subunit vaccine for prevention of SARS... - Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccinesYuxian He
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
J Immunol 173:4050-7. 2004..This study also provides information useful for designing SARS vaccines and understanding the SARS pathogenesis... - Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4Qian Zhao
Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, 10021, USA
AIDS Res Hum Retroviruses 19:947-55. 2003..With a robotic sample processing system, this assay can be used for high-throughput screening of HIV-1 entry inhibitors targeted to the HIV-1 coreceptor CXCR4... - Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundlesA Robert Neurath
Biochemical Virology Laboratory, The Lindsley F Kimball Research Institute of the New York Blood Center, New York, NY 10021, USA
BMC Infect Dis 2:6. 2002.... - CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entryShuwen Liu
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
Eur J Pharmacol 660:460-7. 2011..These findings suggest that CL-385319 can serve as a lead for development of novel virus entry inhibitors for preventing and treating H5N1 influenza A virus infection... - Vaccine design for severe acute respiratory syndrome coronavirusYuxian He
Viral Immunology Laboratory, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10021, USA
Viral Immunol 18:327-32. 2005..It has been demonstrated that the RBD of SARS-CoV S protein contains multiple conformational epitopes capable of inducing highly potent neutralizing antibody responses and protective immunity... - A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infectionJie Yang
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
Fitoterapia 83:348-55. 2012..It has a potential to be developed as a safe and affordable topical microbicide for preventing sexual transmission of HIV... - HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compoundsShuwen Liu
Viral Immunology Laboratory, Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Curr Pharm Des 13:143-62. 2007..The progress in development of those anti-HIV agents targeting gp41, from polypeptides to small-molecule compounds, is reviewed... - Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitorsHong Lu
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
J Virol Methods 107:155-61. 2003.... - Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41Shuwen Liu
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
J Biomol Screen 8:685-93. 2003..Using an Integrated Robotic Sample Processing System, this assay has been applied for high-throughput screening of organic compounds on a large scale for HIV-1 fusion inhibitors targeting gp41... - Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donorChang Zheng Li
Nanfang Hospital, Southern Medical University, Guangzhou, China
Cell Mol Immunol 9:184-90. 2012..Therefore, this platform is very useful for the development of therapeutic antibodies... - A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfacesYe Zhou
Institute of Genetic Engineering, Southern Medical University, Guangzhou, China
Acta Biochim Biophys Sin (Shanghai) 42:575-84. 2010..Using this strategy, we constructed a full-length human antibody display library. DNA sequence analysis and expression analysis indicated that the library constructed had a combinatory expressible, detectable diversity of 6.58 x 10(10)... - A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 virusesLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, New York, New York, United States of America
PLoS ONE 6:e16555. 2011.... - XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41Qian Zhao
Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York 10021, USA
AIDS Res Hum Retroviruses 18:989-97. 2002..But because XTT formazan itself has anti-HIV-1 activity, caution should be exercised when XTT is used to evaluate HIV-1 infectivity... - Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitorsShuwen Liu
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Peptides 24:1303-13. 2003..It suggests that these biophysical techniques can be used in a novel way to study the conformational change of gp41 during virus entry into cells and to identify HIV-1 fusion inhibitors... - Peptide and non-peptide HIV fusion inhibitorsShibo Jiang
Lindsley F Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, NY 10021, USA
Curr Pharm Des 8:563-80. 2002.... - rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigensAngus J MacDonald
Laboratory of Molecular Parasitology, Lindsley F Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, NY 10021, USA
Vaccine 23:3446-52. 2005..Unusually for a helminth product, the rOv-ASP-1 adjuvant augmented not only Th2 but also Th1 responses, the latter property being of potential utility in stimulating anti-viral immune responses... - Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotteShuwen Liu
Institute of Pharmaceutical Sciences of the First Medical University of PLA, PLA Key Lab for Drug Screening, Guangzhou, Guangdong 510515, China
Life Sci 71:1779-91. 2002..These results suggest that tannin may be one of major inhibitors of the HIV-1 gp41 six-helix bundle formation in the herb extracts and that tannin may inhibit HIV-1 entry by disrupting the gp41 six-helix bundle formation... - Research and development of universal influenza vaccinesLanying Du
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Microbes Infect 12:280-6. 2010..This review describes the advancements in the research and development of universal influenza vaccines based on the relatively conserved sequences of M2e, HA, and other proteins of influenza viruses... - Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combinationLifeng Cai
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
FASEB J 26:1018-26. 2012..However, the strong interaction between T20 and T1144 in the covalently linked state may shield their NHR-binding sites, resulting in reduction of the synergistic effect... - Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virusChungen Pan
Lindsley F Kimball Research Institute, New York Blood Center, New York, New York, United States of America
PLoS ONE 5:e9549. 2010..All these mutant residues, except that at NA-91, are located in the viral functional domains, suggesting that they may play roles in the human adaption and virulence of 2009 H1N1pdm... - High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniquesShuwen Liu
Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Curr Pharm Des 10:1827-43. 2004.... - A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stabilityChungen Pan
Lindsley F Kimball Research Institute, New York Blood Center, New York, New York 10065, USA
J Biol Chem 286:28425-34. 2011..coli make this novel protein-based fusion inhibitor a promising candidate for further development as an anti-HIV-1 microbicide or therapeutic for the prevention and treatment of HIV-1 infection... - High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmissionChungen Pan
Lindsley F Kimball Research Institute, The New York Blood Center, New York, NY 10065, USA
Biochem Biophys Res Commun 385:402-7. 2009.... - E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humansChungen Pan
Lindsley F Kimball Research Institute, New York Blood Center and Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
PLoS Curr 1:RRN1044. 2009..These finding suggests that E14-F55 combination in the M2 protein of S-OIV may be a molecular determinant associated with its human-to-human transmission... - Drug-resistant viruses may repair impaired fitness by mutations outside the drug target siteLifeng Cai
Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Future Microbiol 4:507-9. 2009..The work sheds new light on the mechanism of HIV-1 drug resistance, which may be used for the development of new HIV fusion inhibitors with improved efficacy and drug resistance profiles... - Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formationStephen A Gallo
Center for Cancer Research Nanobiology Program, NCI-Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
J Biol Chem 281:18787-92. 2006..This mode of action, although novel for an innate effector molecule, resembles the mechanism of peptidic entry inhibitors based on portions of the gp41 sequence... - Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formationAndrew Vaillant
REPLICor Inc, 500 Cartier Blvd West, Suite 135, Laval, QC, Canada H7V5B7
Antimicrob Agents Chemother 50:1393-401. 2006..This novel antiviral mechanism of action of long PS-ONs has implications for therapy against infection by HIV-1 and other enveloped viruses with type I fusion proteins... - Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodiesGeng Zhang
Laboratory of Immunology, Department of Biology, Tsinghua University, Protein Science Laboratory of MOE, Beijing, P R China
Immunobiology 210:639-45. 2005..These data strongly suggest that ELDKWA-specific antibodies induced by different antigenic formats show different neutralizing activities against HIV-1, which implies another complication in the development of effective vaccines... - Antigenic properties of a transport-competent influenza HA/HIV Env chimeric proteinLing Ye
Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, 1510 Clifton Road, Room 3086 Rollins Research Center, Atlanta, GA 30322, USA
Virology 352:74-85. 2006.... - Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formationYang Xu
Department of Chemistry and Immunology and The Skaggs Institute for Chemical Biology and Worm Institute for Research and Medicine (WIRM, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
J Comb Chem 8:531-9. 2006..From the high-throughput screening assays we utilized, a selective index (SI) value of 4.2 was uncovered for compound 2261, which bodes well for future structure activity investigations and the design of more potent gp41 inhibitors... - Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccinesLanying Du
Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
Virology 353:6-16. 2006..5 months. These results suggested that RBD-rAAV is a promising SARS candidate vaccine... - Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34Lai Xi Wang
Institute of Human Virology, Biotechnology Institute, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
Chembiochem 6:1068-74. 2005..This study suggests that conserved glycosylation modulates the anti-HIV activity and conformations of the gp41 C-peptide, C34... - Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changesEve de Rosny
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892-4555, USA
J Virol 78:2627-31. 2004..We also demonstrate conformational changes in the C heptad of gp41... - Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusionAntony S Dimitrov
Laboratory of Experimental and Computational Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702 1201, USA
Biochemistry 42:14150-8. 2003..Moreover, the observation that the Delta665-683 Env self-inserts its fusion peptide but does not cause fusion suggests that self-insertion of the fusion peptide is not sufficient for HIV-1 Env-mediated fusion... - Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusionJustin T Ernst
Department of Chemistry, Yale University, P.O. Box 208107, New Haven, CT 06520-8107, USA
Angew Chem Int Ed Engl 41:278-81. 2002 - Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccinesWenjun Xiao
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
Vaccine 26:5022-9. 2008.... - The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunizationZhikai Xu
Department of Microbiology, the Fourth Medical University of PLA, Xi an, 710032, People s Republic of China
Biochem Biophys Res Commun 298:552-8. 2002..Phase II clinical trials of these neutralizing MAbs for emergent treatment of patients with HTNV infection in early stages of HRFS are carried out in endemic areas in China... - Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivativesKannan P Naicker
Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W. Lombard Street, Baltimore, MD 21201, USA
Bioorg Med Chem 12:1215-20. 2004..This approach yielded a new analogue (compound 4) that retained the anti-HIV-1 activity with reduced molecular size approaching towards more drug-like character... - Identification of the HIV-1 gp41 core-binding motif--HXXNPFJing-He Huang
Laboratory of Immunology, Department of Biology, Tsinghua University, Protein Science Laboratory of the Ministry of Education, Beijing 100084, PR China
FEBS Lett 580:4807-14. 2006..These data suggest that HXXNPF motif may be a gp41 core-binding sequence and HXXNPF motif-containing molecules can be used as probes for studying the role of the HIV-1 gp41 core in membrane fusion process... - Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion coreLu Lu
Laboratory of Immunology, Department of Biology, Tsinghua University, Beijing Key Laboratory for Protein Therapeutics, Beijing 100084, China
J Biol Chem 283:16723-31. 2008..These results suggest that the gp41 CT may interact with the gp41 core, via the surface-exposed LLP2 domain, to regulate Env-mediated membrane fusion... - Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitorsYuxian He
AIDS Research Center, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
J Virol 82:6349-58. 2008..Therefore, our works provide important information for understanding the core structure of the fusion-active gp41 and for designing novel anti-HIV peptides... - Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigensMei Yun Zhang
CCRNP, CCR, NCI Frederick, NIH, Bldg 469, Rm 131, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
J Virol 82:6869-79. 2008..Its novel conserved conformational epitope on gp41 could be helpful in the design of vaccine immunogens and as a target for therapeutics... - Development of subunit vaccines against severe acute respiratory syndromeLanying Du
Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China
Drugs Today (Barc) 44:63-73. 2008..This suggests that recombinant protein/peptide-based subunit vaccines containing the spike protein, especially the receptor-bind domain of SARS-CoV, could be developed as safe and effective SARS vaccines... - Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifsWeiguo Shi
Beijing Institute of Pharmacology and Toxicology, Pharmaceutical Chemistry, 27 Taiping Road, Beijing 100850, China
Biochem Biophys Res Commun 374:767-72. 2008..These results suggest that these artificial HR sequences, which may serve as structural domains, could be used as templates for the design of novel antiviral peptides against HIV and other viruses with class I fusion proteins... - Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitopeJing Li
Laboratory of Immunology, Department of Biology, Tsinghua University, Beijing 100084, PR China Beijing Key Laboratory for Protein Therapeutics, Beijing 100084, PR China
Biochem Biophys Res Commun 376:60-4. 2008..We found that these changes resulted in significant increase of the antigenicity and immunogenicity of 4E10 epitope. This information is thus useful for rational design of vaccines targeting the HIV-1 gp41 MPER... - Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infectionLanying Du
Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
Vaccine 26:1644-51. 2008.... - Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitorsCatia Teixeira
ITODYS, University Paris 7 CNRS UMR 7086, 1 rue Guy de la Brosse, 75005 Paris, France
Bioorg Med Chem 16:3039-48. 2008..These findings provide guidance for the design and structural modifications of these derivatives for better anti-HIV-1 activity which is important for the development of a new class of entry inhibitors... - Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-Lanying Du
Department of Microbiology, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
J Immunol 180:948-56. 2008..n. vaccination may be the preferred route of administration due to its ability to induce SARS-CoV-specific systemic and mucosal immune responses and its better safety profile... - The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusionMiao Ping Chien
Institute of Chemistry, Academia Sinica, Taipei, Taiwan 11529, Republic of China
FASEB J 22:1179-92. 2008..The temporal order of these fusogenic steps allows construction of a refined model on the Env-mediated cell fusion event... - Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesZhongyu Zhu
Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC Frederick, Inc, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702, USA
Proc Natl Acad Sci U S A 104:12123-8. 2007..These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections... - Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptideJan Munch
Institute of Virology, University of Ulm, 89081 Ulm, Germany
Cell 129:263-75. 2007..Thus, as a highly specific natural inhibitor of the HIV-1 gp41 fusion peptide, VIRIP may lead to the development of another class of antiretroviral drugs... - HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMECAmbrose Y Jong
Division of Hematology Oncology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA, and Department of Life Science, Catholic Fu Jen University, Taiwan, ROC
Biochem Biophys Res Commun 356:899-905. 2007..Our results suggest that HIV-1 gp41 ectodomain and C. neoformans may follow a similar invasion mechanism, possibly actin reorganization and/or membrane activation, during pathogen infections on HBMEC... - The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formationJing He Huang
Laboratory of Immunology, Department of Biology, Tsinghua University, Protein Science Laboratory of the Ministry of Education, Beijing 100084, People s Republic of China
Biochem J 403:565-71. 2007..The HXXNPF motif-containing molecules may be used as probes for studying the role of the HIV-1 gp41 core in the late stage of the membrane-fusion process... - Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal modelLanying Du
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
Vaccine 25:2832-8. 2007..In conclusion, our findings suggest that RBD, which can induce protective antibodies to SARS-CoV, may be further developed as a safe and effective SARS subunit vaccine... - Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panningMei Yun Zhang
Protein Interactions Group, CCRNP, CCR, NCI Frederick, NIH, Frederick, Maryland 21702, USA
J Immunol Methods 317:21-30. 2006..These results may have implications for the selection of novel gp41-specific bcnAbs and other antibodies, and for the development of HIV-1 inhibitors and vaccine immunogens...
Research Grants
- SARS-CoV S Protein Receptor-binding Domain-based VaccinesShibo Jiang; Fiscal Year: 2010..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
- Rational Design of HIV Fusion Inhibitors Targeting gp41Shibo Jiang; Fiscal Year: 2009..Therefore, this research is relevant to public health. ..
- SARS-CoV S Protein Receptor-binding Domain-based VaccinesShibo Jiang; Fiscal Year: 2009..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
- Rational Design of HIV Fusion Inhibitors Targeting gp41Shibo Jiang; Fiscal Year: 2007..Therefore, this research is relevant to public health. ..
- SARS-CoV S Protein Receptor-binding Domain-based VaccinesShibo Jiang; Fiscal Year: 2007..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
- RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 COREShibo Jiang; Fiscal Year: 2003..The long-term goal is to develop novel anti-HIV-1 drugs for chemotherapy of HIV-1 infection and AIDS. ..
- Rational Design of HIV Fusion Inhibitors Targeting gp41Shibo Jiang; Fiscal Year: 2010..Therefore, this research is relevant to public health. ..